Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation

Overview

Journal Clin Hematol Int

Specialty Hematology

Date 2022 Sep 21

PMID 36131129

Authors

Sayako Yuda

Shigeo Fuji

Bipin Savani

Katie S Gatwood

Affiliations

Soon will be listed here.

Abstract

Hematopoietic stem cell transplantation (HSCT) is an integral part of the treatment strategy in patients with a hematological disorder. Chemotherapy-induced nausea and vomiting (CINV) is still an issue in patients who undergo HSCT. While several guidelines for the antiemetic therapy against CINV have been published, there is no detailed information about appropriate antiemetic drugs for each conditioning regimen in HSCT. Various studies reported that the triplet of 5-HT3RA, NK1RA, and dexamethasone appears useful in HSCT. However, each antiemetic has unique adverse effects or interactions with specific drugs. Here, we review the literature relating to clinical trials on the prevention of CINV, and summarize the information to clarify the benefit of antiemetic regimens.

Citing Articles

Impact of dexamethasone on transplant-related mortality in pediatric patients: a multi-site, propensity score-weighted, retrospective assessment.

Paw Cho Sing E, Tomlinson G, Schechter T, Ali M, Phelan R, Rassekh S Support Care Cancer. 2024; 32(8):552.

PMID: 39052128 DOI: 10.1007/s00520-024-08732-8.

Comparison of netupitant/palonosetron with 5-hydroxytryptamine-3 receptor antagonist in preventing of chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.

Zhang H, Zeng Q, Dong T, Chen X, Kuang P, Li J Front Oncol. 2023; 13:1280336.

PMID: 38074658 PMC: 10703172. DOI: 10.3389/fonc.2023.1280336.

References

Svanberg A, Birgegard G . Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting. Oncology. 2015; 89(1):31-6. DOI: 10.1159/000371523. View

Andersen S, Staudacher H, Weber N, Kennedy G, Varelias A, Banks M . Pilot study investigating the effect of enteral and parenteral nutrition on the gastrointestinal microbiome post-allogeneic transplantation. Br J Haematol. 2019; 188(4):570-581. DOI: 10.1111/bjh.16218. View

Hesketh P, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I . Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014; 25(7):1340-1346. PMC: 4071755. DOI: 10.1093/annonc/mdu110. View

Nakagaki M, Barras M, Curley C, Butler J, Kennedy G . A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Support Care Cancer. 2016; 25(2):607-613. DOI: 10.1007/s00520-016-3445-2. View

Rapoport B, Chasen M, Gridelli C, Urban L, Modiano M, Schnadig I . Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3.... Lancet Oncol. 2015; 16(9):1079-1089. DOI: 10.1016/S1470-2045(15)00035-2. View

Bechtel T, McBride A, Crawford B, Bullington S, Hofmeister C, Benson Jr D . Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. Support Care Cancer. 2014; 22(11):2911-6. DOI: 10.1007/s00520-014-2248-6. View

Chawla S, Grunberg S, Gralla R, Hesketh P, Rittenberg C, Elmer M . Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer. 2003; 97(9):2290-300. DOI: 10.1002/cncr.11320. View

Seguy D, Duhamel A, Ben Rejeb M, Gomez E, Buhl N, Bruno B . Better outcome of patients undergoing enteral tube feeding after myeloablative conditioning for allogeneic stem cell transplantation. Transplantation. 2012; 94(3):287-94. DOI: 10.1097/TP.0b013e3182558f60. View

Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla R, Bruera E . 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016; 27(suppl 5):v119-v133. DOI: 10.1093/annonc/mdw270. View

10.

Uchida M, Kato K, Ikesue H, Ichinose K, Hiraiwa H, Sakurai A . Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation. Pharmacotherapy. 2013; 33(9):893-901. PMC: 3817520. DOI: 10.1002/phar.1294. View

11.

Inzucchi S . Clinical practice. Management of hyperglycemia in the hospital setting. N Engl J Med. 2006; 355(18):1903-11. DOI: 10.1056/NEJMcp060094. View

12.

Hesketh P, Aapro M, Street J, Carides A . Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer. 2009; 18(9):1171-7. DOI: 10.1007/s00520-009-0737-9. View

13.

Chou C, Chen Y, Yu Y, Chang K, Hwang W, Teng C . Palonosetron versus first-generation 5-hydroxytryptamine type 3 receptor antagonists for emesis prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2014; 93(7):1225-32. DOI: 10.1007/s00277-014-2038-8. View

14.

Beckerson J, Szydlo R, Hickson M, Mactier C, Innes A, Gabriel I . Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies. Clin Nutr. 2018; 38(2):738-744. DOI: 10.1016/j.clnu.2018.03.008. View

15.

Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruessel J . The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transplant. 2010; 46(6):784-9. DOI: 10.1038/bmt.2010.205. View

16.

Aapro M, Fabi A, Nole F, Medici M, Steger G, Bachmann C . Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic.... Ann Oncol. 2010; 21(5):1083-8. DOI: 10.1093/annonc/mdp584. View

17.

Warr D, Street J, Carides A . Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer. 2010; 19(6):807-13. DOI: 10.1007/s00520-010-0899-5. View

18.

Aapro M, Walko C . Aprepitant: drug-drug interactions in perspective. Ann Oncol. 2010; 21(12):2316-2323. DOI: 10.1093/annonc/mdq149. View

19.

McMillen K, Coghlin-Dickson T, Adintori P . Optimization of nutrition support practices early after hematopoietic cell transplantation. Bone Marrow Transplant. 2020; 56(2):314-326. DOI: 10.1038/s41409-020-01078-9. View

20.

Berger M, Ettinger D, Aston J, Barbour S, Bergsbaken J, Bierman P . NCCN Guidelines Insights: Antiemesis, Version 2.2017. J Natl Compr Canc Netw. 2017; 15(7):883-893. DOI: 10.6004/jnccn.2017.0117. View